Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab Rollover Protocol
NCT00378482Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2007
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of tremelimumab in colorectal cancer (CRC), melanoma, prostate cancer (PCa), renal cell carcinoma (RCC), solid tumor, sponsored by AstraZeneca. Started Mar 2007; status: completed.
02
Drugs
tremelimumab
03
Conditions
colorectal cancer (CRC)melanomaprostate cancer (PCa)renal cell carcinoma (RCC)solid tumor
Beyond the preview
Go deeper on NCT00378482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378482.